Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

R8657

Sigma-Aldrich

Razoxane

>98% (HPLC)

Synonym(s):

(±)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane, (±)-1,2-Bis(3,5-dioxopiperazinyl)propane, 1,2-Bis(3,5-dioxo-1-piperazinyl)propane, 4,4′-Propylenebis(2,6-piperazinedione), ICI 59118, ICRF 159, NSC 129943, Razoxin, Tepirone, Troxozone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H16N4O4
CAS Number:
21416-67-1
Molecular Weight:
268.27
EC Number:
244-379-2
MDL number:
MFCD00430424
UNSPSC Code:
12352200
PubChem Substance ID:
329824039
NACRES:
NA.77

Quality Level

100

Assay

>98% (HPLC)

form

solid

solubility

DMSO: 40 mg/mL

storage temp.

room temp

SMILES string

CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

InChI

1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)

InChI key

BMKDZUISNHGIBY-UHFFFAOYSA-N

Biochem/physiol Actions

Razoxane is clinically active against angiogenesis and metastasis. Razoxane specifically inhibits topoisomerase II without inducing DNA strand breaks (topo II catalytic inhibitor). It is an antimitotic agent with immunosuppressive properties. Razoxane inhibits blood-borne and lymphatic metastases in different experimental models. Studies have shown that razoxane inhibits specifically the vasculogenic mimicry of B16F10 melanoma cells.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown.
K Hellmann
Clinical & experimental metastasis, 20(2), 95-102 (2003-04-23)
W Rhomberg et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 175(3), 102-104 (1999-03-27)
Angiosarcomas of the heart are rare neoplasms bearing an unfavorable prognosis. In recent series, the median survival is about 5 months. The response to radiation therapy is uncertain. A 65-year-old copper smith with an angiosarcoma of the right atrium and
Dana M Walker et al.
Pediatric blood & cancer, 60(4), 616-620 (2012-09-06)
Acute lymphoblastic (ALL) and myeloid leukemia (AML) account for approximately 26% of pediatric cancers. Anthracyclines are widely used to treat these leukemias, but dosing is limited by cardiotoxicity. Data support the efficacy of dexrazoxane as a cardioprotectant in children; however
K Hellmann et al.
Cancer treatment reviews, 18(4), 225-240 (1991-12-01)
Razoxane blocks cell division in the G2/M phase of the cell generation cycle and appears to normalize tumour neovasculature development. These were the principal reasons for the examination and probably for the demonstration of the radiosensitizing activity of Rz. Specially
Steven E Lipshultz et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(10), 1042-1049 (2012-03-01)
Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy. Children with high-risk ALL were randomly assigned to receive doxorubicin alone (n
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service